JP2013526497A5 - - Google Patents

Download PDF

Info

Publication number
JP2013526497A5
JP2013526497A5 JP2013509505A JP2013509505A JP2013526497A5 JP 2013526497 A5 JP2013526497 A5 JP 2013526497A5 JP 2013509505 A JP2013509505 A JP 2013509505A JP 2013509505 A JP2013509505 A JP 2013509505A JP 2013526497 A5 JP2013526497 A5 JP 2013526497A5
Authority
JP
Japan
Prior art keywords
formula
salt
solvate
diyl
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013509505A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013526497A (ja
JP5727002B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/057021 external-priority patent/WO2011141326A1/de
Publication of JP2013526497A publication Critical patent/JP2013526497A/ja
Publication of JP2013526497A5 publication Critical patent/JP2013526497A5/ja
Application granted granted Critical
Publication of JP5727002B2 publication Critical patent/JP5727002B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013509505A 2010-05-08 2011-05-03 置換ヘテロサイクリルベンジルピラゾール類およびその使用 Expired - Fee Related JP5727002B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10004855.2 2010-05-08
EP10004855 2010-05-08
PCT/EP2011/057021 WO2011141326A1 (de) 2010-05-08 2011-05-03 Substituierte heterocyclylbenzyl-pyrazole und ihre verwendung

Publications (3)

Publication Number Publication Date
JP2013526497A JP2013526497A (ja) 2013-06-24
JP2013526497A5 true JP2013526497A5 (https=) 2014-06-26
JP5727002B2 JP5727002B2 (ja) 2015-06-03

Family

ID=44063276

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013509505A Expired - Fee Related JP5727002B2 (ja) 2010-05-08 2011-05-03 置換ヘテロサイクリルベンジルピラゾール類およびその使用

Country Status (26)

Country Link
US (2) US20130172311A1 (https=)
EP (1) EP2569312B1 (https=)
JP (1) JP5727002B2 (https=)
KR (1) KR20130108997A (https=)
CN (1) CN103003269B (https=)
AR (1) AR081368A1 (https=)
AU (1) AU2011252223A1 (https=)
BR (1) BR112012028651A2 (https=)
CA (1) CA2798375A1 (https=)
CO (1) CO6640218A2 (https=)
CR (1) CR20120570A (https=)
CU (1) CU20120157A7 (https=)
DO (1) DOP2012000284A (https=)
EA (1) EA201291167A1 (https=)
EC (1) ECSP12012288A (https=)
ES (1) ES2462522T3 (https=)
IL (1) IL222851A0 (https=)
MA (1) MA34939B1 (https=)
MX (1) MX2012012960A (https=)
PE (1) PE20130228A1 (https=)
PH (1) PH12012502202A1 (https=)
SG (1) SG185459A1 (https=)
TN (1) TN2012000531A1 (https=)
TW (1) TW201200510A (https=)
UY (1) UY33369A (https=)
WO (1) WO2011141326A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2685875C (en) * 2007-05-01 2015-10-06 Hill's Pet Nutrition, Inc. Methods and compositions for diagnosing osteoarthritis in a feline
CA2687306A1 (en) * 2007-05-18 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
PE20130228A1 (es) * 2010-05-08 2013-03-15 Bayer Ip Gmbh Heterociclilbencilpirazoles sustituidos
EP2867230B1 (en) 2012-07-02 2020-02-12 Monsanto Technology LLC Process for the preparation of 3,5-disubstituted-1,2,4-oxadiazoles
EP2888253A4 (en) * 2012-08-24 2016-01-06 Univ Texas HETEROCYCLIC HIF ACTIVITY MODULATORS FOR THE TREATMENT OF DISEASES
US20140073634A1 (en) * 2012-08-24 2014-03-13 Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center Heterocyclic modulators of hif activity for treatment of disease
ES2691643T3 (es) 2012-08-24 2018-11-28 Board Of Regents, The University Of Texas System Moduladores heterocíclicos de la actividad de HIF para el tratamiento de enfermedades
WO2015130790A2 (en) 2014-02-25 2015-09-03 Board Of Regents, University Of Texas System Salts of heterocyclic modulators of hif activity for treatment of disease
US10191597B2 (en) 2015-06-30 2019-01-29 Synaptics Incorporated Modulating a reference voltage to preform capacitive sensing
KR102544307B1 (ko) * 2017-01-13 2023-06-15 닛산 가가쿠 가부시키가이샤 방향족 디아민 화합물 전구체의 제조 방법
CN115944626B (zh) * 2022-12-08 2024-04-19 桂林医学院附属医院 小分子化合物在制备抗缺氧或缺血再灌注损伤药物中的应用
WO2025096662A1 (en) * 2023-10-30 2025-05-08 Pretzel Therapeutics, Inc. Compositions and inhibitors of polrmt

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610726B2 (en) * 2001-06-29 2003-08-26 North Shore-Long Island Jewish Research Institute Compositions and agents for modulating cellular proliferation and angiogenesis
AU2004228057A1 (en) 2003-04-03 2004-10-21 Merck & Co., Inc. Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
AU2004275694B2 (en) 2003-06-30 2008-03-06 Bizbiotech Co., Ltd. Compounds, compositions and methods
CN1842332A (zh) * 2003-06-30 2006-10-04 Hif生物公司 化合物、组合物及方法
GB0508472D0 (en) * 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
WO2007065010A2 (en) 2005-12-02 2007-06-07 Hif Bio, Inc. Anti-angiogenesis compounds
CA2687306A1 (en) * 2007-05-18 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
AU2009316019A1 (en) * 2008-11-14 2010-05-20 Bayer Intellectual Property Gmbh Heterocyclically substituted aryl compounds as HIF inhibitors
DE102008057344A1 (de) * 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Aminoalkyl-substituierte Aryl-Verbindungen und ihre Verwendung
WO2010054764A1 (de) * 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Heteroaromatische verbindungen zur verwendung als hif-inhibitoren
EP2202232A1 (en) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
ES2405054T3 (es) 2009-01-23 2013-05-30 Bristol-Myers Squibb Company Derivados de pirazol-1,2,4-oxadiazol como agonistas de esfingosina-1-fosfato
PE20130228A1 (es) * 2010-05-08 2013-03-15 Bayer Ip Gmbh Heterociclilbencilpirazoles sustituidos

Similar Documents

Publication Publication Date Title
JP2013526497A5 (https=)
JP2010523476A5 (https=)
JP6810275B2 (ja) 3−フェニル−2,3,4,8,9,10−ヘキサヒドロピラノ[2,3−f]クロメン誘導体およびその光学異性体の合成方法
JP2015517579A5 (https=)
JP2014507455A5 (https=)
JP2019528276A5 (https=)
JP2019524883A5 (https=)
JP2013523896A5 (https=)
JP2016500661A5 (https=)
JP2011137006A5 (https=)
JP2013530150A5 (https=)
JP2012513481A5 (https=)
JP2016528273A5 (https=)
RS53710B2 (sr) Jedinjenja kao antagonisti b1 bradikinina
JP2013533253A5 (https=)
JP2013512277A5 (https=)
JP2016531126A5 (https=)
JP2010516702A5 (https=)
JP2010522710A5 (https=)
JPWO2023195529A5 (https=)
JP2014505017A5 (https=)
JP2007532627A5 (https=)
WO2015030010A1 (ja) ピロール誘導体の製造方法及びその中間体
JP6426302B2 (ja) 3−[(ベンゾ[d][1,3]ジオキソラン−4−イル)−オキシ]−3−アリールプロピルアミン型化合物およびその適用
JP2019513829A5 (https=)